What is Spyre Therapeutics, Inc.'s net change in cash?

Spyre Therapeutics, Inc. (SYRE) reported net change in cash of $11.46M in Q1 2026.

How has Spyre Therapeutics, Inc.'s net change in cash changed year-over-year?

Spyre Therapeutics, Inc.'s net change in cash increased by 128.0% year-over-year, from -$40.93M to $11.46M.

What does net change in cash mean?

Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Spyre Therapeutics, Inc. SYRE Net Change in Cash

Net Change in Cash at other companies

Bristol-Myers SquibbBMY

-$635M-220%

Eli LillyLLY

-$1.99B-1,035%

PfizerPFE

$563M+50.1%

Johnson & JohnsonJNJ

$1.98B-86.2%

Merck & Co.MRK

-$9.29B-103%

AbbVieABBV

$4.16B+1,293%

Other financials

Income statement

See full

Revenue-—

Operating income-$45.6M+14.8%

Net income-$69.0M-54.1%

EPS (diluted)-$0.74-23.3%

Balance sheet

See full

Cash & equivalents$97.2M+100%

Total debt$4.3M-9.6%

Total equity$670.8M+39.0%

Total assets$764.0M+34.1%

Cash flow

See full

Operating cash flow-$57.4M-40.0%

CapEx-—

Free cash flow-$39.4M-26.8%

Valuation

See full

Market cap$7.67B+307%

Profitability

See full

Operating margin-39,428.9%-49,795pp

Net margin-52,939.7%-61,871pp

FCF margin-3,442.8%-3,807pp

Returns & leverage

See full

Return on equity-31.1%-10.7pp

Debt / equity0.1×+0.1×

Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s net change in cash?: Spyre Therapeutics, Inc. (SYRE) reported net change in cash of $11.46M in Q1 2026.
How has Spyre Therapeutics, Inc.'s net change in cash changed year-over-year?: Spyre Therapeutics, Inc.'s net change in cash increased by 128.0% year-over-year, from -$40.93M to $11.46M.
What does net change in cash mean?: Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.